ARCHIVES

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

This article is from The Cancer Letter archive.

Vol. 37 No. 32 | August 12, 2011

Download PDF Visit The Full Archive

Related Articles

Center Directors To Hear “Creative” Approach to Funding Cancer Control

February 25, 1983

BMS, Exelixis To Collaborate On Drug Development.

July 27, 2001

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

July 12, 1991

NCAB, President’s Cancer Panel honor the late Paul Calabresi.

June 11, 2004

NCI To Recompete Drug Discovery Groups In 2003 As Program Nears Its 20th Year

November 29, 2002

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

December 9, 2005